Skip to main content
Medical information Clinical review pending

Genetic Testing

RYR2 Gene Ventricular Tachycardia Catecholaminergic Polymorphic Type 1 Genetic Test

Genetic test analyzing the RYR2 gene to identify mutations linked to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), a serious heart rhythm disorder. Helps in early diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific fasting is required. Inform the laboratory about any medications you are taking. A clinical history and family history (pedigree chart if available) are helpful for interpretation. Discuss preparation details with your doctor or the laboratory.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the RYR2 Gene Ventricular Tachycardia Catecholaminergic Polymorphic Type 1 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Personal or family history of unexplained fainting (syncope).
  • ✓History of seizures or sudden cardiac arrest in family members.
  • ✓Symptoms like palpitations, dizziness, or light-headedness, especially during exercise or stress.
  • ✓Diagnosis of CPVT.
  • ✓Family history of Long QT Syndrome or other inherited arrhythmia syndromes.
  • ✓Evaluation before starting certain medications known to affect heart rhythm.
02

In plain language

What this test helps you understand

Identifies genetic mutations in the RYR2 gene associated with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). This information can aid in diagnosis, risk assessment, and management strategies for individuals with suspected or confirmed CPVT or a family history of related conditions.
The RYR2 Gene Ventricular Tachycardia Catecholaminergic Polymorphic Type 1 NGS Genetic DNA Test is an advanced diagnostic tool used to identify genetic mutations associated with potentially life-threatening heart conditions. This test analyzes the RYR2 gene, which plays a critical role in regulating calcium release within heart muscle cells. Mutations in this gene can lead to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), a condition characterized by dangerous abnormal heart rhythms, often triggered by physical exertion or emotional stress. Understanding your genetic predisposition through this test can significantly impact your health management and help in preventing sudden cardiac events. Results provide insights into the presence of specific mutations. A genetic counseling session is recommended to help interpret the results and discuss potential implications for you and your family.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific fasting is required. Inform the laboratory about any medications you are taking. A clinical history and family history (pedigree chart if available) are helpful for interpretation. Discuss preparation details with your doctor or the laboratory.
SampleBlood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the RYR2 gene for specific mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific mutations within the RYR2 gene. It may not detect all possible mutations. A negative result does not completely rule out CPVT or other genetic heart conditions. Results should be interpreted in conjunction with clinical findings and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is an inherited heart rhythm disorder that can cause fast, dangerous heartbeats (ventricular tachycardia), often triggered by physical activity or emotional stress.
Individuals experiencing symptoms like fainting during exercise, palpitations, or dizziness, or those with a family history of unexplained fainting or sudden cardiac death, should discuss this test with their doctor.
The test requires a blood sample. A clinical history and family history are important for interpreting the results. Genetic counseling may be recommended.
Results indicate whether specific mutations in the RYR2 gene were found. Interpretation requires clinical context and may involve genetic counseling to understand the implications for you and your family.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
We have laboratory branches across Kenya, including Nairobi, Mombasa, and Kisumu. We also offer home sample collection services. Contact us to book.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp